Monte Rosa Therapeutics, Inc.
GLUE
$18.15
-$0.53-2.84%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -44.50M | -46.14M | -27.08M | -12.30M | 46.89M |
| Total Depreciation and Amortization | 2.67M | 2.76M | 2.73M | 2.72M | 2.62M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4.32M | 3.72M | 3.26M | 3.57M | 3.64M |
| Change in Net Operating Assets | 141.00K | -3.36M | 121.52M | -28.71M | -98.64M |
| Cash from Operations | -37.37M | -43.01M | 100.43M | -34.72M | -45.49M |
| Capital Expenditure | -1.87M | -767.00K | -651.00K | -1.70M | -1.59M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -259.13M | -64.30M | 38.79M | 27.02M | -98.64M |
| Cash from Investing | -261.00M | -65.07M | 38.14M | 25.32M | -100.23M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 349.52M | 29.98M | 348.00K | 365.00K | 14.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -21.19M | -357.00K | -- | -- | -- |
| Cash from Financing | 328.34M | 29.62M | 348.00K | 365.00K | 14.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 29.97M | -78.46M | 138.91M | -9.03M | -145.71M |